SINGLE CHAIN VARIABLE FRAGMENT (SCFV) ELONGATION MUTANTS
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
May 16, 2014
filing date -
May 16, 2014
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The present invention relates to the provision of single chain variable fragment (scFv) elongation mutants. In addition, the present invention relates to a pharmaceutical composition comprising said scFv elongation mutants, as well as a nucleotide sequence encoding said scFv elongation mutants, a vector comprising said nucleotide sequence or a host cell expressing said nucleotide sequence. Particular embodiments relate to elongation mutants of the scFv-h3D6 which is derived from monoclonal antibody mAb-h3D6 (bapineuzumab). It is further disclosed a method of prevention or treatment of a patient in risk of suffering, or already diagnosted as suffering, Alzheimer disease that comprises the administration to said patient of an effective amount of the scFv elongation mutants of scFv-h3D6.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully